Advanced

Repeated open application tests with methyldibromoglutaronitrile in dermatitis patients with and without hypersensitivity to methyldibromoglutaronitrile

Isaksson, Marléne LU ; Gruvberger, Birgitta LU and Bruze, Magnus LU (2007) In Dermatitis 18(4). p.203-207
Abstract
Background: Contact allergy to and allergic contact dermatitis from methyldibromoglutaronitrile (MDBGN) have been frequently reported since the 1990s. Objective: This study was initiated to help determine the optimal test preparation for MDBGN and to help determine the clinical relevance of such a contact allergy. Method. In 38 patients with positive (32 patients) or doubtful (6 patients) patch-test reactions to at least one of four test preparations of MDBGN in petrolatum at 1.0%, 0.5%, 0.3%, and 0.1% (all weight per weight [w/w]), a repeated open application test (ROAT) with moisturizers with and without MDBGN at 0.03% w/w was conducted on patients' upper arms for a maximum of 4 weeks. Seven patients not hypersensitive to MDBGN served as... (More)
Background: Contact allergy to and allergic contact dermatitis from methyldibromoglutaronitrile (MDBGN) have been frequently reported since the 1990s. Objective: This study was initiated to help determine the optimal test preparation for MDBGN and to help determine the clinical relevance of such a contact allergy. Method. In 38 patients with positive (32 patients) or doubtful (6 patients) patch-test reactions to at least one of four test preparations of MDBGN in petrolatum at 1.0%, 0.5%, 0.3%, and 0.1% (all weight per weight [w/w]), a repeated open application test (ROAT) with moisturizers with and without MDBGN at 0.03% w/w was conducted on patients' upper arms for a maximum of 4 weeks. Seven patients not hypersensitive to MDBGN served as controls and went through the same procedure. Results: Nineteen (59.4%) of the 32 MDBGN-allergic patients developed a positive ROAT result on the arm on which the moisturizer containing MDBGN was applied whereas no patients with doubtful or negative reactions to MDBGN reacted (p = .002). A statistically significant association was found between the patch-test reactivity and the outcome of the ROAT (p < .001). Conclusion: Patch testing with MDBGN at 0.3% and 0.1% will miss clinically relevant patch-test reactions to MDBGN. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Dermatitis
volume
18
issue
4
pages
203 - 207
publisher
BC Decker
external identifiers
  • wos:000251640100003
  • scopus:37349070965
ISSN
1532-8163
DOI
10.2310/6620.2007.06042
language
English
LU publication?
yes
id
22371c19-2126-4491-9137-bfebe5a6515c (old id 966136)
date added to LUP
2008-01-29 14:03:10
date last changed
2017-01-01 05:18:06
@article{22371c19-2126-4491-9137-bfebe5a6515c,
  abstract     = {Background: Contact allergy to and allergic contact dermatitis from methyldibromoglutaronitrile (MDBGN) have been frequently reported since the 1990s. Objective: This study was initiated to help determine the optimal test preparation for MDBGN and to help determine the clinical relevance of such a contact allergy. Method. In 38 patients with positive (32 patients) or doubtful (6 patients) patch-test reactions to at least one of four test preparations of MDBGN in petrolatum at 1.0%, 0.5%, 0.3%, and 0.1% (all weight per weight [w/w]), a repeated open application test (ROAT) with moisturizers with and without MDBGN at 0.03% w/w was conducted on patients' upper arms for a maximum of 4 weeks. Seven patients not hypersensitive to MDBGN served as controls and went through the same procedure. Results: Nineteen (59.4%) of the 32 MDBGN-allergic patients developed a positive ROAT result on the arm on which the moisturizer containing MDBGN was applied whereas no patients with doubtful or negative reactions to MDBGN reacted (p = .002). A statistically significant association was found between the patch-test reactivity and the outcome of the ROAT (p &lt; .001). Conclusion: Patch testing with MDBGN at 0.3% and 0.1% will miss clinically relevant patch-test reactions to MDBGN.},
  author       = {Isaksson, Marléne and Gruvberger, Birgitta and Bruze, Magnus},
  issn         = {1532-8163},
  language     = {eng},
  number       = {4},
  pages        = {203--207},
  publisher    = {BC Decker},
  series       = {Dermatitis},
  title        = {Repeated open application tests with methyldibromoglutaronitrile in dermatitis patients with and without hypersensitivity to methyldibromoglutaronitrile},
  url          = {http://dx.doi.org/10.2310/6620.2007.06042},
  volume       = {18},
  year         = {2007},
}